BIOV fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
BioVersys AG is a clinical stage biopharmaceutical company, which engages in identifying, development, and commercializing novel antibacterial products for infections caused by multi-drug resistant (MDR) bacteria. It is involved in the research and development programs that address nosocomial infections of Acinetobacter baumannii and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
BIOV does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company